SSG
FDMT icon

Summit Securities Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Summit Securities Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.75K Buy
+432
New +$4.21K ﹤0.01% 952
2025
Q3 		– Sell
-977
Closed -$3.63K – 1125
2025
Q2 		$3.63K Buy
+977
New +$3.43K ﹤0.01% 1003
2024
Q2 		– Sell
-142
Closed -$5K – 639
2024
Q1 		$5K Buy
+142
New +$3.62K ﹤0.01% 374

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Summit Securities Group's FDMT Position: Q2 2026 in Review

Summit Securities Group opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 432 shares worth $5.75K. The stake represents ﹤0.01% of the portfolio and ranks #952 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in FDMT as recently as Q2 2025.

Summit Securities Group first reported a position in FDMT in Q1 2024 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Summit Securities Group held 432 shares of 4D Molecular Therapeutics worth $5.75K as of Q2 2026.
  • 4D Molecular Therapeutics was a new Summit Securities Group position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #952 holding.
  • Summit Securities Group first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.